Parallel Bio, a biotech company unlocking the human body’s own power to cure disease, announced the appointment of Dwight Morrow, a 17-year GSK veteran, as vice president and head of platform. The company also welcomed its first scientific advisors: Darrell Irvine, a professor at Massachusetts Institute of Technology and investigator at the Howard Hughes Medical Institutes, and Nima Aghaeepour, associate professor and associate vice chair of research – data science, at Stanford University.
“Parallel Bio melds my passion for drug discovery with a rare opportunity to be on the leading edge of curing disease through the immune system”
“Dwight, Darrell, and Nima are an impeccable trio that combine pharmaceutical industry know-how with cutting-edge scientific research,” said Robert DiFazio, co-founder and CEO of Parallel Bio. “Their expertise will further advance our human immune system in a dish and bring new treatments to more patients faster than ever.”
Recommended AI News: Fastly Acquires Fanout to Unlock Real-Time App Development at the Edge
Parallel Bio’s platform combines immune organoids with artificial intelligence and robotics to uniquely represent organoids as a population. Organoids are 3D, self-assembling models of human biology, or so-called “mini organs,” that mimic the structure and function of parts of the human body and their response to disease or treatment as if the organoids were individual patients.
In his new role, Dwight Morrow is responsible for ongoing development of the platform and building the team of scientists to advance it. He has more than two decades of experience in high throughput screening, building drug discovery and development platforms, and taking drug candidates from target discovery to approval at both large pharmaceutical companies and startups.
Recommended AI News: OmniML Secures $10 Million to Accelerate AI Computing on Edge Devices
“Parallel Bio melds my passion for drug discovery with a rare opportunity to be on the leading edge of curing disease through the immune system,” Morrow said. “The company’s novel approach to combining immune organoids with robotics and AI is opening an entirely new way to discover and develop drugs with pinpoint accuracy across entire populations.”
Most recently, Morrow served as vice president of platform innovation at Rubius Therapeutics and earlier as vice president of preclinical development at Magenta Therapeutics. At GSK, he served in roles including senior director of target sciences and as a director in the stem cell and regenerative medicines groups.
Recommended AI News: Ermetic Receives Strategic Investment from Splunk Ventures
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.